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C3 metabolism in acute glomerulonephritis: Implications for sites of
complement activation. Immunochemical and metabolic studies of com-
plement were performed in I 1 patients with acute poststreptococcal
glomerulonephritis (AGN) to determine the mechanism(s) of hypocom-
plementemia. Four patients with profound reduction in serum C3
showed metabolic changes comparable to those seen in hypocomple-
mentemic mesangiocapillary GN (MCGN), that is, nonlinear plasma
disappearance of '251.C3 and a gross (that is, 30-fold) reduction in C3
synthesis (0.01 to 0.02 mg/kg/hr); fractional catabolic rate (FCR) and
extravascular/intravascular distribution (EV/IV) ratio were also in-
creased (3.02 to 6.99%/hr; 1.14 to 2.96, respectively). The remaining
seven patients had less (or no) reduction in C3 and showed normal or
elevated values for all three metabolic parameters; six had linear plasma
disappearance curves. Metabolic data in five simultaneously studied
control subjects were FCR: 1.56 to 2.12%/hr; EV/IV ratio: 0.12 to 0.41
and synthesis rate: 0.30 to 0.52 mg/kg/hr. C3 nephritic factor (NeF)
could not be detected in any sera and a significant reduction in serum
CS accompanied the changes in C3 (r = 0.89; P < 0.001). Previous
studies of C3 NeF-associated MCGN show that the fluid phase alterna-
tive pathway convertase seen in this condition has little or no CS
cleaving ability. We propose, therefore, that complement activation in
AGN occurs via a surface-bound convertase which is capable of
cleaving both C3 and CS. The glomerular capillary could provide such a
site for activation.
Metabolisme du C3 lors de Ia glomerulonephrite aiguë: Implications
pour les sites de l'activation du complement. Des etudes immunochimi-
ques et métaboliques du complement ont etC effectuCes chez 11 malades
atteints de glomerulonéphrite aiguë poststreptococcique (AGN) pour
determiner le(s) mécanisme(s) de l'hypocomplementCmie. Quatre ma-
lades ayant une reduction profonde du C3 serique prCsentaient des
modifications metaboliques comparables a celles observées lors de Ia
GN mesangio-capillaire (MCGN) hypocomplementaire, c'est-à-dire une
disparition plasmatique non linéaire du '251.C3 et une reduction mar-
quee (30 fois) de Ia synthèse du C3 (0,01 a 0,02 mglkg/hr); Ia proportion
fractionnaire catabolique (FCR) et le rapport Ia distribution extravascu-
laire/intravasculaire (EV/IV) Ctaient egalement augmentes (3,02 a
6,99%/hr; 1,14 a 2,96, respectivement). Les sept autres malades avaient
une reduction moindre (ou nulle) du C3 et avaient les valeurs normales
ou Clevees des trois paramCtres mCtaboliques; six avaient des courbes
de disparition plasmatique linéaires. Les donnCes metaboliques chez
cinq sujets contrôles étudiés simultanément Ctaient FCR: 1,56 a
2,12%/hr; rapport EV/IV: 0,12 àO,41 et vitesse de synthêse: 0,30 àO,52
mg/kg/hr. Le facteur C3 nCphritique (NeF) ne pouvait Ctre dCtecté dans
aucun serum, et une reduction significative du CS sérique accompagnait
les modifications de C3 (r = 0,89; P < 0,001). Des etudes anténeures
des MCGN associées au C3 NeF ont montré que Ia convertase de Ia
voie alterne en phase liquidienne observCe dans cette condition, n'a pas
ou peu de capacité de clivage. Nous proposons donc que l'activation du
complement au cours des AGN se produise grace a une convertase liée
a Ia surface, capable de diver le C3 et le CS. Le capillaire glomCrulaire
pourrait fournir un tel site d'activation.
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Several forms of human glomerulonephritis (GN) are associ-
ated with reduced levels of complement components [1]. Acute
poststreptococcal glomerulonephritis (AGN) and mesangiocap-
illary glomerulonephritis (MCGN) show changes consistent
with predominant activation of the alternative pathway with
marked reduction of C3 and usually normal levels of Clq, C4,
and C2. Complement activation in MCGN (especially type 2 or
dense deposit disease) may be associated with the presence of
C3 nephritic factor (C3 NeF), an oligoclonal IgG which pro-
longs the half-life of the alternative pathway C3 convertase,
C3bBb [2]; this leads to exhaustive activation of the C3 amplifi-
cation loop [3—5]. These patients exhibit changes in C3 turnover
that reflect hypercatabolism and, in particular, altered compart-
mental distribution and reduced C3 synthesis [6].
The nature of the complement abnormality in AGN is less
clear. There is considerable evidence that the glomerular lesion
follows deposition of circulating immune complexes (CIC) [7]
and might therefore be expected to show utilization of the
classical pathway of complement. This conflicts with the pat-
tern of complement abnormality [8] and the variable incidence
of detectable CIC in these patients during the acute (hypocom-
plementemic) phase of illness [9, 10]. C3 NeF is rarely found in
the serum and the lack of conclusive studies of C3 metabolism
in AGN leaves unexplained the cause of the profound reduction
in C3 concentration.
In this study, complement abnormalities were examined in 11
patients presenting with typical AGN. The basis of the marked
change in serum C3, observed in some patients, was analyzed
by the performance of turnover studies using a highly purified,
biologically active preparation of human C3. Comparisons were
made between the pattern of complement utilization in these
patients and that exhibited by previously reported patients with
MCGN. Our observations show the C3 metabolic abnormalities
of AGN to be comparable to those in MCGN; gross reduction in
C3 synthesis was chiefly responsible for the marked fall in this
component. Unlike C3 NeF-associated hypocomplementemic
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curve, hence t'/2 not calculated; FCR, fractional catabolic rate; EV/IV, extravascular/intravascular
MCGN, significant reduction in C5 accompanied the changes in
C3. We concluded that patients with AGN exhibited type 2 C3
hypercatabolism, a feature of alternative pathway activation
(and of MCGN) and that this occurred on a fixed surface (such
as the glomerular capillary) rather than in the fluid phase. This
would explain the absence of C3 NeF in the serum despite
evidence of predominant alternative pathway activation.
Methods
Patients. Ten patients (nine male, one female; age range: 6 to
22 years) were investigated as soon as possible after admission
to the King Edward VIII Hospital, Durban, South Africa. The
eleventh patient (a male aged 13 years) was studied at the Prince
Henry Hospital in Sydney, Australia. The clinical presentation
of each patient was typical of acute glomerulonephritis, While
only five out of 11 patients had evidence of recent skin or throat
infection, the true incidence of antecedent infection (pyodermal
or pharyngeal) could not be assessed because of the difficulty in
obtaining an accurate history from both the patients and their
parents. In all patients the anti-streptolysin 0 (ASOT) and anti-
DNase B (A-DNase B) titers were elevated (see Table 1).
Patients 5, 6, and 8 (see Tables I and 2) underwent renal
biopsy to confirm the diagnosis of AGN: Each showed typical
exudative acute diffuse proliferative glomerulonephritis. No
attempt was made to obtain biopsy specimens from the other
patients as streptococcal infection remains almost the sole
cause of AGN in African children [11]. The clinical course was
typical, with all patients recovering promptly despite their
severity of presentation. Five had transient oliguria, none
required dialysis, all were hypertensive, ten were discharged
within 30 days and one at 53 days, and none were on any
medication at the time of discharge.
Measurement of complement components. These were mea-
sured serially on blood obtained during the C3 turnover studies.
Sera were separated from clotted blood, stored at —70°C, and
thawed only at the time of assay. Levels of Clq, C2, C3, C4,
CS, and Factor B were measured on all samples by either laser
nephelometry [12] or radial immunodiffusion using monospecif-
ic antisera (Dako, Behring, Marburg, West Germany). C3 NeF
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Table 1. Results of laboratory parameters in patients with AGN
Blood urea Serum albumin C3 CS Clq.BA
mmo!es/!iter gui/er ASOT A-DNase BT mg/dl %NHS % binding
1 16.7 25 800 600 6 44 82
2 14.8 32 1600 400 I 25 38
3 17.6 33 320 400 l2 55 27
4 11.0 29 1600 400 1 21 55
5 6.0 30 800 400 47 95 20
6 9.0 32 800 400 94 102 42
7 3.6 32 400 200 159 109 17
8 7.9 26 1000 400 19 64 80
9 14.1 30 640 400 149 136 15
10 6.7 42 800 100 118 77 17
II 22.7 26 1600 400 79 74 32
Patient no.
Normal range 2.5 to 6.0 35 to 50 0 to 200 0 to 80 65 to 125 80 to 120 0 to IS
Abbreviations: ASOT, anti-streptolysis 0 titer; A-DNase BT, anti-DNase B titer; Clq.BA, CIq binding assay for immune complexes.
Table 2. C3 metabolic data in patients with AGN
T'/2 FCR—% plasma EV/lV
hr pool/hr ratio
Synthesis rate
mg/kg/hr
Serum C3
mg/d!
1° NL 4.40 1.14 0.02 6.0
2 NL 3.02 2.73 0.01 1.0
3" NL 5.33 1.18 0.02 12.0
4" NL 6.99 2.96 0.02 1.0
5 NL 1.88 3.00 0.47 47.0
6 52 3.11 1.30 0.41 94.0
7 66 1.89 1.55 0.50 159.0
8 82 1.83 0.97 0.32 19.0
9 52 2.96 0.47 0.69 149.0
10 50 1.75 0.24 0.51 118.0
11 56 2.50 1.77 0.86 79.0
Normal subjects
(N =5)
Mean
Range
Abbreviations: NL, non-linear plasma
distribution.
"Calculations for FCR and EV/IV ratios were derived from data obtained in the first 72 hr after injection.
was detected by two-dimensional electrophoresis [13]; positive
sera from two patients with MCGN were used as the control
reagent.
dC were measured by two methods: a modified Raji cell
assay [14] and the Clq binding assay [15]. (It should be noted
that levels are higher in normal, non-infected black Africans
than in normal Indian and white racial groups [16]).
C3 metabolic studies
Preparation of C3. C3 was prepared from sera donated by
two healthy, hepatitis-B surface antigen-negative volunteers.
The method was the same as that described by Lachmann and
Hobart [17]. Purity was tested by Ouchterlony double diffusion
in agarose against anti-whole human serum and on polyacryl-
amide gel electrophoresis in sodium dodecyl sulfate. These
showed one dominant line consistent with C3 and one faint
contaminating line. C3 conversion was checked by two-dimen-
sional electrophoresis which showed less than 5% of the
preparation to be in the C3c position. Functional activity was
tested by a hemolytic assay [17] and found to be 80% of that
observed in a fresh normal human serum (NHS) of comparable
C3 concentration.
Protein iodination. The purified C3 was labelled by a modifi-
cation of the chloramine-T method [6]. Further testing showed
that the percentage C3 conversion and C3 hemolytic activity
had not been altered by iodination (these were tested as
described above). Human albumin was added to reduce self-
irradiation. Preparations were sterilized by Millipore filtration,
cultured for aerobic and anaerobic organisms, and pyrogen-
tested in rabbits.
Turnover protocol. The study was approved by the Ethics
Committees of the hospitals and informed consent was obtained
from each patient (or parent). Doses of radioactivity were
comparable to those used (by us and others) in previous studies.
C3 metabolic studies were commenced as soon as consent was
obtained. The average time interval betwen the initiation of the
study and the onset of symptoms of GN was 13 days. Five
healthy medical staff and the 11 patients with AGN each
received approximately I to 5 Ci 1251 C3. Thyroidal uptake of
unbound iodide was blocked by oral administration of 60 mg
potassium iodide thrice daily for at least 24 hr prior to the
injection of isotope and throughout the period of sampling. The
duration of the studies was 4 to 7 days. Plasma and urine
samples were processed as previously described [6]. Each
subject had at least one sample of urine tested for protein-bound
radioactivity: 2 ml of urine were precipitated with trichloroace-
tic acid (20%), using NHS as a carrier and the precipitated
radioactivity was then counted. Serum C3 concentrations were
measured daily or second daily throughout the turnover. Only
data from patients in a steady state (that is, a variation in serum
C3 of < 20% during the study) were used for analysis by the
following methods: (1) integrated rate equation analysis of
Nosslin [18] and (2) exponential analysis of Matthews [19]
where urine data were incomplete or renal failure was present.
Statistical analysis. A Student's t test was used to calculate
the level of significance of differences between serum concen-
trations. Correlations between paired data (C3 and CS concen-
trations) were assessed by linear regression analysis and calcu-
lation of the coefficient 'r'.
Results
C3 metabolism. Disappearance was nonlinear in five patients
and linear in the remaining six patients (Fig. 1). Values for
fractional catabolic rate (FCR), extravascular/intravascular dis-
tribution (EV/IV) ratio and C3 synthesis for each patient and
the control group are shown in Table 2. Patients 1 to 4 (Table 2)
had profoundly depressed C3 synthesis as well as elevation of
the FCR and EV/IV ratio; these abnormalities were associated
with a rapid temporary rise in the ratio of free to protein-bound
radioactivity in contrast to the stable patterns observed in
simultaneously studied control subjects. FCR in the other seven
patients ranged from normal to moderately elevated values
(Table 2) and their synthesis rates were normal or elevated.
Serum C3 correlated with synthesis rate (r = 0.77; P <0.01) but
not with the FCR or EV/IV ratio. (A numerical value of 1.0
mg/dl was used in the calculation of the metabolic parameters in
those patients with undetectable C3 levels).
Serological parameters. Table I provides details of signifi-
cant laboratory data. All values given are from the same
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Fig. 1. Plasma disappearance curves for '251-labelled C3 in five normal
subjects (shaded area) and in two patients with AGN. Linear (0) and
nonlinear (•) decay patterns are shown.
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samples taken before commencement of the metabolic study
except for the ASOT and A-DNase BT where the maximum
titer is shown.
Complement. Figure 2 shows the levels of complement
components on the day of commencement of C3 turnover. In
general the classical pathway components were normal or
elevated. Depressed serum C3 was seen in six and low C5 in
seven of the II patients. There was a significant correlation
between C3 and CS (r = 0.89; P < 0.001, Fig. 3). C3 NeF was
not found in any patient, No further fall in serum C3 and C5
occurred subsequent to the turnover studies and both compo-
nents had returned to normal by the time of discharge.
Circulating immune complexes. Modest elevations of CIC
were detected by the Raji-cell assay and the Clq binding assay
(Fig. 2).
There was no association between clinical or biochemical
abnormalities and the pattern of C3 metabolism. Neither the C3
concentration nor the presence and concentration of CIC
correlated with the interval between the onset of clinical
symptoms and the initiation of the C3 metabolic studies.
Discussion
This study defines the basis for the profound change in C3
concentration observed in some patients with AGN. The meta-
bolic abnormalities seen in almost half of our patients were very
similar to those observed in MCGN [6]. A gross reduction in C3
synthesis and a nonlinear pattern of plasma disappearance were
the outstanding features in both disorders. (This nonlinear
pattern has been attributed previously to changes in compart-
mental distribution and generation of more slowly catabolized
C3 metabolites such as C3d [6]). The metabolic changes are in
contrast to those observed in diseases associated with classical
pathway activation (for example, systemic lupus erythematosus
(SLE) where the plasma disappearance of the radiolabelled C3
is linear and hypercatabolism plays the major role in lowering
this component [6, 20]). Four of our patients showed this linear
accelerated decay pattern. The factors determining these differ-
ent patterns of C3 disappearance in our patients are unknown
although it seems likely that they reflect studies performed at
varying stages in the course of AGN; the patients with relative-
ly minor C3 changes and linear decay recovered without further
fall in C3 concentration, It is doubtful that measurement of
immune complexes alone would provide an effective index of
the degree of C3 activation and serial metabolic studies would
be required to accurately define the evolution of the C3
abnormality.
A feature of the complement studies in our patients was the
detection of low C5 levels and the highly significant correlation
between values for C3 and C5 (r = 0.89, Fig. 2). Such a finding
is in contrast to that reported in patients with C3 NeF-
associated MCGN and alternative pathway activation (where
CS metabolism remained normal despite profound reduction in
C3 concentration [20]) and therefore appears to reflect a funda-
mental difference in the site of complement activation in these
two forms of GN. The reduction in C3 concentration in C3 NeF-
positive MCGN has been attributed to the stabilization of the
C3 convertase (C3bBb) [21]. Sissons et al [20] proposed that the
absence of C5 cleavage was due to the formation of a fluid
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Fig. 2. Plasma concentrations of complement
components and circulating immune
complexes in patients with AGN. The shaded
area denotes the normal range. C2, C4, and
CS were measured in %NHS, C3 in mg/dl, and
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Fig. 3. Correlation between the concentrations of C5 and C3 in the
serum of patients with AGN. (r 0.89; P < 0.001)
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phase enzyme with little or no C5 cleaving activity. In contrast,
they found both hypercatabolism and reduced C5 levels in
patients with SLE and in one subject with acute glomerulone-
phritis, suggesting the formation of a surface-bound convertase.
We propose, therefore, that complement activation in AGN
occurs via surface-bound cleavage of both C3 and C5. This
reaction could involve either or both complement pathways at
different stages of the illness. Such a hypothesis would explain
the failure to detect C3 NeF in the serum of our patients despite
profound hypocomplementemia.
While the site of complement activation in AGN requires
further study, it is tempting to relate the disproportionate C3
activation to the presence of streptococcal antigen(s), Recently,
Lange, Seligson, and Cronin [22] found glomerular deposition
of endostreptosin—a cytoplasmic constituent of group A strep-
tococci—in renal biopsy specimens from patients early in the
course of AGN. However, other studies [23] have shown that
the neuraminidase-containing nephritogenic streptococcus was
capable of modifying autologous IgG resulting in the formation
of glomerular-fixed immune complexes. Logically, such capil-
lary deposition of antigen or complexes could be relevant to the
site of complement activation. The possibility of a glomerular
capillary-bound alternative pathway C3 convertase is supported
by the finding of factor B in the glomerular capillary of patients
with AGN and depressed C3 levels [24]. Further experiments in
vitro will be required to define this aspect of complement
metabolism in patients with AGN.
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